rs119103267

chr1-12009641-C-T

Variant summary

Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM2PM5PP2PP3PP5_Very_Strong

The NM_014874.4(MFN2):c.2119C>T(p.Arg707Trp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000453 in 1,614,174 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R707Q) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.00027 ( 0 hom., cov: 33)

Exomes 𝑓: 0.00047 ( 1 hom. )

Consequence

MFN2
NM_014874.4 missense

Scores

Clinical Significance

Pathogenic/Likely pathogenic criteria provided, multiple submitters, no conflicts P:23O:2

Conservation

PhyloP100: 2.89

Variant links:

Genes affected

MFN2 (HGNC:16877): (mitofusin 2) This gene encodes a mitochondrial membrane protein that participates in mitochondrial fusion and contributes to the maintenance and operation of the mitochondrial network. This protein is involved in the regulation of vascular smooth muscle cell proliferation, and it may play a role in the pathophysiology of obesity. Mutations in this gene cause Charcot-Marie-Tooth disease type 2A2, and hereditary motor and sensory neuropathy VI, which are both disorders of the peripheral nervous system. Defects in this gene have also been associated with early-onset stroke. Two transcript variants encoding the same protein have been identified. [provided by RefSeq, Jul 2008]

MFN2 links:

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 14 ACMG points.

PM2

Very rare variant in population databases, with high coverage;

PM5

Other missense variant is known to change same aminoacid residue: Variant chr1-12009642-G-C is described in ClinVar as [Likely_pathogenic]. Clinvar id is 637750.Status of the report is criteria_provided_single_submitter, 1 stars.

PP2

Missense variant where missense usually causes diseases, MFN2

PP3

MetaRNN computational evidence supports a deleterious effect, 0.835

PP5

Variant 1-12009641-C-T is Pathogenic according to our data. Variant chr1-12009641-C-T is described in ClinVar as [Likely_pathogenic]. Clinvar id is 2280.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr1-12009641-C-T is described in Lovd as [Pathogenic]. Variant chr1-12009641-C-T is described in Lovd as [Likely_pathogenic]. Variant chr1-12009641-C-T is described in Lovd as [Pathogenic].

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	MANE	UniProt
MFN2	NM_014874.4 linkuse as main transcript	c.2119C>T	p.Arg707Trp	missense_variant	18/19	ENST00000235329.10

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	TSL	MANE	Appris	UniProt
MFN2	ENST00000235329.10 linkuse as main transcript	c.2119C>T	p.Arg707Trp	missense_variant	18/19	1	NM_014874.4	P1	O95140-1

Frequencies

GnomAD3 genomes

AF:

0.000269

AC:

AN:

152168

Hom.:

Cov.:

show subpopulations

Gnomad AFR

AF:

0.0000965

Gnomad AMI

AF:

0.00

Gnomad AMR

AF:

0.00

Gnomad ASJ

AF:

0.00

Gnomad EAS

AF:

0.00

Gnomad SAS

AF:

0.00

Gnomad FIN

AF:

0.0000942

Gnomad MID

AF:

0.00

Gnomad NFE

AF:

0.000529

Gnomad OTH

AF:

0.00

GnomAD3 exomes

AF:

0.000251

AC:

AN:

251494

Hom.:

AF XY:

0.000206

AC XY:

AN XY:

135922

show subpopulations

Gnomad AFR exome

AF:

0.00

Gnomad AMR exome

AF:

0.0000578

Gnomad ASJ exome

AF:

0.00

Gnomad EAS exome

AF:

0.00

Gnomad SAS exome

AF:

0.0000327

Gnomad FIN exome

AF:

0.0000462

Gnomad NFE exome

AF:

0.000519

Gnomad OTH exome

AF:

0.00

GnomAD4 exome

AF:

0.000472

AC:

690

AN:

1461888

Hom.:

Cov.:

AF XY:

0.000474

AC XY:

345

AN XY:

727242

show subpopulations

Gnomad4 AFR exome

AF:

0.0000597

Gnomad4 AMR exome

AF:

0.0000224

Gnomad4 ASJ exome

AF:

0.00

Gnomad4 EAS exome

AF:

0.0000504

Gnomad4 SAS exome

AF:

0.000116

Gnomad4 FIN exome

AF:

0.00

Gnomad4 NFE exome

AF:

0.000584

Gnomad4 OTH exome

AF:

0.000430

GnomAD4 genome

AF:

0.000269

AC:

AN:

152286

Hom.:

Cov.:

AF XY:

0.000228

AC XY:

AN XY:

74454

show subpopulations

Gnomad4 AFR

AF:

0.0000962

Gnomad4 AMR

AF:

0.00

Gnomad4 ASJ

AF:

0.00

Gnomad4 EAS

AF:

0.00

Gnomad4 SAS

AF:

0.00

Gnomad4 FIN

AF:

0.0000942

Gnomad4 NFE

AF:

0.000529

Gnomad4 OTH

AF:

0.00

Alfa

AF:

0.000388

Hom.:

Bravo

AF:

0.000246

TwinsUK

AF:

0.00

AC:

ALSPAC

AF:

0.000778

AC:

ESP6500AA

AF:

0.00

AC:

ESP6500EA

AF:

0.000581

AC:

ExAC

AF:

0.000329

AC:

EpiCase

AF:

0.000436

EpiControl

AF:

0.000593

ClinVar

Significance: Pathogenic/Likely pathogenic

Submissions summary: Pathogenic:23Other:2

Revision: criteria provided, multiple submitters, no conflicts

LINK: link

Submissions by phenotype

Charcot-Marie-Tooth disease, axonal, autosomal recessive, type 2a2b;

Pathogenic:4

Pathogenic, no assertion criteria provided	literature only	OMIM	May 06, 2008	- -
Likely pathogenic, criteria provided, single submitter	clinical testing	3billion	May 22, 2022	The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.025%). Missense changes are a common disease-causing mechanism. In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.84; 3Cnet: 0.86). Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000002280). A different missense change at the same codon (p.Arg707Pro) has been reported to be associated with MFN2 related disorder (ClinVar ID: VCV000637750 / PMID: 22492563). Therefore, this variant is classified as likely pathogenic according to the recommendation of ACMG/AMP guideline. -
Pathogenic, criteria provided, single submitter	clinical testing	Institute of Human Genetics, University of Leipzig Medical Center	Jan 30, 2023	_x000D_This variant was identified together with NM_014874.4:c.1160+1G>A. Criteria applied: PM3_VSTR, PS3_SUP, PP3 -
Likely pathogenic, criteria provided, single submitter	curation	SIB Swiss Institute of Bioinformatics	May 31, 2018	This variant is interpreted as a Likely Pathogenic, for Charcot-Marie-Tooth disease, axonal, type 2A2B, in Autosomal Recessive manner. The following ACMG Tag(s) were applied: PM2 => Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium. PP3 => Multiple lines of computational evidence support a deleterious effect on the gene or gene product. PS3 => Well-established functional studies show a deleterious effect (PMID:26085578). -

not provided

Pathogenic:4

Pathogenic, criteria provided, single submitter	clinical testing	Revvity Omics, Revvity	Aug 13, 2021	- -
Pathogenic, criteria provided, single submitter	clinical testing	CeGaT Center for Human Genetics Tuebingen	Apr 01, 2024	MFN2: PM3:Very Strong, PM2:Supporting, PM5:Supporting, PP1, PS3:Supporting -
Pathogenic, criteria provided, single submitter	clinical testing	GeneDx	Apr 19, 2023	R707W was identified in the homozygous state in multiple independent families with a lipodystrophic syndrome (Capel et al., 2018); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 28492532, 22492563, 25025039, 28251916, 26306937, 24126688, 20350294, 26085578, 26114802, 28414270, 31589614, 24957169, 24819634, 31980526, 33415332, 32376792, 29867446, 32916636, 33502018, 34426522, 29358271, 26392352, 25231362, 35641312, 20008656, 30158064, 18458227) -
Pathogenic, criteria provided, single submitter	clinical testing	Eurofins Ntd Llc (ga)	Jan 23, 2017	- -

MFN2-related disorder

Pathogenic:3

Pathogenic, criteria provided, single submitter	clinical testing	PreventionGenetics, part of Exact Sciences	Feb 20, 2024	The MFN2 c.2119C>T variant is predicted to result in the amino acid substitution p.Arg707Trp. This variant has previously been reported in several individuals with diverse phenotypes. In an individual with severe early-onset axonal neuropathy and lipodystrophy, this variant was found in the homozygous state (Nicholson et al. 2008. PubMed ID: 18458227). In another study, six patients from five families presented with a lipodystrophy with variable Charcot-Marie-Tooth features; each of these individuals harbored the p.Arg707Trp variant in the homozygous state (Capel et al. 2018. PubMed ID: 30158064). In another family with two brothers affected with multiple symmetric lipomatosis and neuropathy, whole exome sequencing identified they were also homozygous for the c.2119C>T variant (Sawyer et al. 2015. PubMed ID: 26085578). In another family with three affected children with early-onset Charcot-Marie-Tooth disease, all were found to be compound heterozygous for the c.2119C>T variant and a second plausible causative variant (Calvo et al. 2009. PubMed ID: 20008656). Lastly, this variant was found in the compound heterozygous state with an exon 7-8 deletion in an individual with suspected Charcot-Marie-Tooth disease (Carr et al. 2015. PubMed ID: 26114802). Functional studies in fibroblasts show that the p.Arg707Trp variant impairs MFN2-MFN2 protein interactions in mitochondria, making mitochondria prone to perinuclear aggregation (Sawyer et al. 2015. PubMed ID: 26085578). In summary, this evidence suggests the c.2119C>T variant is inherited in an autosomal recessive manner and is pathogenic for disease. -
Pathogenic, criteria provided, single submitter	clinical testing	Women's Health and Genetics/Laboratory Corporation of America, LabCorp	Mar 08, 2022	Variant summary: MFN2 c.2119C>T (p.Arg707Trp) results in a non-conservative amino acid change located in the Fzo/mitofusin HR2 domain (IPR006884) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00025 in 251494 control chromosomes (gnomAD). c.2119C>T has been reported in the literature in multiple individuals affected with MFN2-Related Disorders, including one homozygote diagnosed with severe early onset axonal neuropathy (e.g. Nicholson_2008), and several compound heterozygotes diagnosed with Charcot-Marie-Tooth disease (e.g. Calvo_2009, Brozkova_2013, Pipis_2020). These data indicate that the variant is very likely to be associated with disease and are consistent with an autosomal recessive inheritance pattern. Additionally, affected individuals (e.g. Braathen_2010) and unaffected individuals have been reportes as heterozygous carriers, therefore the relationship of this variant to autosomal dominant disease is unclear. At least one publication reports experimental evidence evaluating an impact on protein function, showing that the variant protein resulted in mitochondrial aggregation and defects in homo-oligomerization (Sawyer_2015). Twelve ClinVar submitters have assessed the variant since 2014: four classified the variant as likely pathogenic, and eight as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
Pathogenic, criteria provided, single submitter	clinical testing	Illumina Laboratory Services, Illumina	Dec 19, 2018	Across a selection of the available literature, the MFN2 c.2119C>T (p.Arg707Trp) missense variant has been identified in a total of 11 individuals with MFN2-related disorders, including in a homozygous state in four individuals, (two of whom are related), in a compound heterozygous state in four individuals, and in a heterozygous state in three individuals (Nicholson et al. 2008; Calvo et al. 2009; Braathen et al. 2010; Sitarz et al. 2012; Brozkova et al. 2013; Hoyer et al. 2014; Sawyer et al. 2015; Carr et al. 2015). The variant was also found in a heterozygous state in several asymptomatic parents, consistent with an autosomal recessive pattern of inheritance. MFN2-related disorders have also been reported to follow an autosomal dominant pattern of inheritance which was observed through four generations of one family in a study by Braathen et al. (2010). The p.Arg707Trp variant was absent from at least 602 evaluated control alleles (Nicholson et al. 2008; Braathen et al. 2010) and is reported at a frequency of 0.000581 in the European American population of the Exome Sequencing Project. Functional studies in U2OS cells homozygous for the p.Arg707Trp variant demonstrate a reduced ability to form homotypic MFN2 protein interactions in vitro and to tubulate mitochondria which were more prone to aggregation (Sawyer et al. 2015). The p.Arg707Trp variant is located in a well-conserved residue in a known functional domain that is thought to permit homotypic protein interaction as well as heterotypic binding to MFN1 (Sawyer et al. 2015). Based on the collective evidence, the p.Arg707Trp variant is classified as pathogenic for MFN2-related disorders. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. -

Charcot-Marie-Tooth disease type 2A2

Pathogenic:2

Pathogenic, criteria provided, single submitter	clinical testing	Baylor Genetics	Apr 12, 2019	This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868]. -
Likely pathogenic, criteria provided, single submitter	clinical testing	Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine	Feb 11, 2019	The p.Arg707Trp variant in MFN2 has been reported in the heterozygous state in 4 probands with clinical features of Charcot-Marie-Tooth disease type 2A (CMT2A; Braathen 2010, Sitarz 2012, BroÅ¾kovÃ¡ 2013, Bansagi 2017). It has also been reported in the compound heterozygous or homozygous state in at least 9 individuals with CMT2A-related neuropathy and lipomatosis or lipodystrophy (Nicholson 2008, Calvo 2009, Carr 2015, Sawyer 2015, Rocha 2017, Capel 2018). The variant segregated with neuropathy and lipomatosis/lipodystrophy in at least 4 affected members of 3 families (Calvo 2009, Rocha 2017, Capel 2018). This variant has also been identified in the heterozygous state in individuals without overt signs of neuropathy (Nicholson 2008, Calvo 2009, BroÅ¾kovÃ¡ 2013, Carr 2015, Rocha 2017) and in 0.05% (66/129186) of European chromosomes by gnomAD (http://gnomad.broadinstitute.org). However, this is consistent with the fact that variable expressivity including sub-clinical, late-onset neuropathy has been reported for CMT2A (ZÃ¼chner 2013). Computational prediction tools and conservation analysis suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. Furthermore, analysis of patient fibroblasts suggest that the p.Arg707Trp variant may impair mitochondrial function (Sawyer 2015). In summary, although additional studies are required to fully establish its clinical significance, the p.Arg707Trp variant meets criteria to be classified as likely pathogenic for autosomal dominant CMT2A, with homozygous or compound heteroygous occurences likely leading to a more severe course of disease that may include lipomatosis and/or lipodystrophy. ACMG/AMP Criteria applied: PM3_Strong, PP3, PS3_Supporting, PS4_Supporting. -

Charcot-Marie-Tooth disease, axonal, autosomal recessive, type 2a2b;;C4721887:Charcot-Marie-Tooth disease type 2A2;CN305336:Neuropathy, hereditary motor and sensory, type 6A

Pathogenic:2

Pathogenic, criteria provided, single submitter	clinical testing	Fulgent Genetics, Fulgent Genetics	Mar 22, 2022	- -
Pathogenic, criteria provided, single submitter	clinical testing	Center for Genomics, Ann and Robert H. Lurie Children's Hospital of Chicago	Mar 30, 2021	MFN2 NM_014874.3 exon 18 p.Arg707Trp (c.2119C>T): This variant has been reported in the literature in the heterozygous, compound heterozygous, or homozygous state in several individuals with axonal neuropathy, segregating with at least 3 affected family members within 2 families (Nicholson 2008 PMID:18458227, Calvo 2009 PMID:20008656, Brozkova 2013 PMID:24126688, Hoyer 2014 PMID:25025039, Sawyer 2015 PMID:26085578, Bansagi 2017 PMID:28251916). This variant has also been reported in individuals with multiple symmetric lipomatosis in addition to neuropathy (Carr 2015 PMID:26114802, Sawyer 2015 PMID:26085578). This variant is present in 0.05% (66/129186) of European alleles in the Genome Aggregation Database (http://gnomad.broadinstitute.org/variant/1-12069698-C-T). Please note, disease causing variants may be present in control databases at low frequencies, reflective of the general population, carrier status, and/or variable expressivity. This variant is also present in ClinVar, with several labs classifying this variant as pathogenic or likely pathogenic (Variation ID:2280). Evolutionary conservation and computational predictive tools suggest that this variant may impact the protein. In addition, a functional study in fibroblasts has shown a deleterious effect of this variant (Sawyer 2015 PMID:26085578). However, this study may not accurately represent in vivo biological function. In summary, this variant is classified as pathogenic based on the data above. -

Charcot-Marie-Tooth disease, axonal, autosomal recessive, type 2a2b;;C4721887:Charcot-Marie-Tooth disease type 2A2

Pathogenic:1Other:1

Likely pathogenic, criteria provided, single submitter	research	HudsonAlpha Institute for Biotechnology, HudsonAlpha Institute for Biotechnology	Sep 26, 2022	PS3_Moderate, PS4_Moderate (for AD CMT) or PM3_Strong (for AR CMT), PP1, PP3 -
not provided, no classification provided	phenotyping only	GenomeConnect - Invitae Patient Insights Network	-	Variant interpreted as Pathogenic and reported on 03-02-2020 by Lab Invitae. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information. -

Charcot-Marie-Tooth disease

Pathogenic:1

Pathogenic, criteria provided, single submitter

clinical testing

Molecular Genetics Laboratory, London Health Sciences Centre

- -

Multiple symmetric lipomatosis

Pathogenic:1

Pathogenic, no assertion criteria provided

literature only

OMIM

May 06, 2008

- -

Inborn genetic diseases

Pathogenic:1

Pathogenic, criteria provided, single submitter

clinical testing

Ambry Genetics

Nov 04, 2022

The c.2119C>T (p.R707W) alteration is located in exon 18 (coding exon 16) of the MFN2 gene. This alteration results from a C to T substitution at nucleotide position 2119, causing the arginine (R) at amino acid position 707 to be replaced by a tryptophan (W)._x000D_ _x000D_ Based on the available evidence, the MFN2 c.2119C>T (p.R707W) alteration is classified as pathogenic for autosomal recessive MFN2-related neuropathy; however, it is unlikely to be causative of autosomal dominant MFN2-related neuropathy. Based on data from gnomAD, the T allele has an overall frequency of 0.025% (71/282876) total alleles studied. The highest observed frequency was 0.051% (66/129186) of European (non-Finnish) alleles. This alteration was reported in the homozygous state or in trans with another MFN2 variant in multiple individuals with axonal neuropathy and lipodystrophy (Nicholson, 2008; Calvo, 2009; Carr, 2015; Sawyer, 2015; Rocha, 2017; Capel, 2018). Heterozygous parents with affected children have been reported to be asymptomatic (Nicholson, 2008; Carr, 2015; Rocha, 2017). This amino acid position is well conserved in available vertebrate species. Functional analysis in patient fibroblasts demonstrated that the p.R707W alteration impairs mitofusin 2 homodimer formation leading to mitochondrial aggregation (Sawyer, 2015). This alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, this alteration is classified as pathogenic. -

Peripheral axonal neuropathy

Pathogenic:1

Pathogenic, criteria provided, single submitter

clinical testing

Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics

Dec 25, 2019

- -

Charcot-Marie-Tooth disease type 2

Pathogenic:1

Pathogenic, criteria provided, single submitter

clinical testing

Invitae

Jan 31, 2024

This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 707 of the MFN2 protein (p.Arg707Trp). This variant is present in population databases (rs119103267, gnomAD 0.05%). This missense change has been observed in individual(s) with Charcot-Marie-Tooth disease and/or multiple symmetric lipomatosis and neuropathy (PMID: 18458227, 20008656, 20350294, 22492563, 25025039, 26085578, 26114802, 28251916, 28414270, 30158064, 33415332). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 2280). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on MFN2 protein function. Experimental studies have shown that this missense change affects MFN2 function (PMID: 26085578). For these reasons, this variant has been classified as Pathogenic. -

Tip-toe gait

Pathogenic:1

Likely pathogenic, no assertion criteria provided

clinical testing

Practice for Gait Abnormalities, David Pomarino, Competency Network Toe Walking c/o Practice Pomarino

Jun 14, 2022

- -

Neuropathy, hereditary motor and sensory, type 6A

Pathogenic:1

Pathogenic, criteria provided, single submitter

clinical testing

Mendelics

May 04, 2022

- -

Hereditary motor and sensory neuropathy with optic atrophy;C2079538:Charcot-Marie-Tooth disease, type 2A

Other:1

not provided, no classification provided

phenotyping only

GenomeConnect, ClinGen

Variant classified as Likely pathogenic and reported on 03-29-2017 by Lab or GTR ID 26957. GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant. -

Computational scores

Source: dbNSFP v4.3

Name

Calibrated prediction

Score

Prediction

AlphaMissense

Uncertain

0.37

BayesDel_addAF

Pathogenic

0.21

BayesDel_noAF

Pathogenic

0.41

Cadd

Pathogenic

Dann

Pathogenic

1.0

DEOGEN2

Uncertain

0.79

D;D

Eigen

Uncertain

0.48

Eigen_PC

Uncertain

0.46

FATHMM_MKL

Uncertain

0.90

LIST_S2

Uncertain

0.96

D;.

M_CAP

Uncertain

0.19

MetaRNN

Pathogenic

0.84

D;D

MetaSVM

Pathogenic

1.0

MutationAssessor

Benign

1.4

L;L

MutationTaster

Benign

1.0

A;A;A

PrimateAI

Uncertain

0.66

PROVEAN

Uncertain

-2.8

D;D

REVEL

Pathogenic

0.84

Sift

Uncertain

0.0050

D;D

Sift4G

Uncertain

0.013

D;D

Polyphen

1.0

D;D

Vest4

0.87

MVP

0.98

MPC

0.81

ClinPred

0.82

GERP RS

4.4

RBP_binding_hub_radar

0.0

RBP_regulation_power_radar

1.7

Varity_R

0.60

gMVP

0.68

Splicing

Name

Calibrated prediction

Score

Prediction

SpliceAI score (max)

0.0

Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Variant summary

Frequency

Consequence

Scores

Clinical Significance

Conservation

ACMG classification

Transcripts

RefSeq

Ensembl

Frequencies

ClinVar

Submissions by phenotype

Computational scores

Splicing

Publications

LitVar

Other links and lift over